The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling

Alexander M. Scherbakov, Danila V. Sorokin, Victor V. Tatarskiy, Nikolai Prokhorov, Svetlana E. Semina, Lev M. Berstein, Mikhail A. Krasil'Nikov

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Metformin, a biguanide antidiabetic drug, is used to decrease hyperglycemia in patients with type 2 diabetes. Recently, the epidemiological studies revealed the potential of metformin as an anti-tumor drug for several types of cancer, including breast cancer. Anti-tumor metformin action was found to be mediated, at least in part, via activation of adenosine monophosphate-activated protein kinase (AMPK) - intracellular energy sensor, which inhibits the mammalian target of rapamycin (mTOR) and some other signaling pathways. Nevertheless, some patients can be non-sensitive or resistant to metformin action. Here we analyzed the mechanism of the formation of metformin-resistant phenotype in breast cancer cells and its role in estrogen receptor (ER) regulation. The experiments were performed on the ER-positive MCF-7 breast cancer cells and metformin-resistant MCF-7 subline (MCF-7/M) developed due to long-term metformin treatment. The transcriptional activity of NF-κB and ER was measured by the luciferase reporter gene analysis. The protein expression was determined by immunoblotting (Snail1, (phospho)AMPK, (phospho)IκBα, (phospho)mTOR, cyclin D1, (phospho)Akt and ERα) and immunohistochemical analysis (E-cadherin). We have found that: 1) metformin treatment of MCF-7 cells is accompanied with the stimulation of AMPK and inhibition of growth-related proteins including IκBα, NF-κB, cyclin D1 and ERα; 2) long-term metformin treatment lead to the appearance and progression of cross-resistance to metformin and tamoxifen; the resistant cells are characterized with the unaffected AMPK activity, but the irreversible ER suppression and constitutive activation of Akt/Snail1 signaling; 3) Akt/Snail1 signaling is involved into progression of metformin resistance. The results presented may be considered as the first evidence of the progression of cross-resistance to metformin and tamoxifen in breast cancer cells. Importantly, the acquired resistance to both drugs is based on the constitutive activation of Akt/Snail1/E-cadherin signaling that opens new perspectives to overcome the metformin/tamoxifen resistance of breast cancer.

Original languageEnglish (US)
Pages (from-to)281-292
Number of pages12
JournalIUBMB Life
Volume68
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Metformin
Cell Communication
Estrogen Receptors
Cells
Breast Neoplasms
Growth
Adenosine Monophosphate
Protein Kinases
Tamoxifen
Chemical activation
Cyclin D1
Sirolimus
Cadherins
Tumors
Biguanides
Estrogen Receptor beta
MCF-7 Cells
Medical problems
Luciferases
Reporter Genes

Keywords

  • breast cancer
  • cell signaling
  • epithelial-mesenchymal transition
  • metformin
  • signal transduction
  • signal transduction pathways

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Cell Biology

Cite this

Scherbakov, A. M., Sorokin, D. V., Tatarskiy, V. V., Prokhorov, N., Semina, S. E., Berstein, L. M., & Krasil'Nikov, M. A. (2016). The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. IUBMB Life, 68(4), 281-292. https://doi.org/10.1002/iub.1481

The phenomenon of acquired resistance to metformin in breast cancer cells : The interaction of growth pathways and estrogen receptor signaling. / Scherbakov, Alexander M.; Sorokin, Danila V.; Tatarskiy, Victor V.; Prokhorov, Nikolai; Semina, Svetlana E.; Berstein, Lev M.; Krasil'Nikov, Mikhail A.

In: IUBMB Life, Vol. 68, No. 4, 01.04.2016, p. 281-292.

Research output: Contribution to journalArticle

Scherbakov, AM, Sorokin, DV, Tatarskiy, VV, Prokhorov, N, Semina, SE, Berstein, LM & Krasil'Nikov, MA 2016, 'The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling', IUBMB Life, vol. 68, no. 4, pp. 281-292. https://doi.org/10.1002/iub.1481
Scherbakov, Alexander M. ; Sorokin, Danila V. ; Tatarskiy, Victor V. ; Prokhorov, Nikolai ; Semina, Svetlana E. ; Berstein, Lev M. ; Krasil'Nikov, Mikhail A. / The phenomenon of acquired resistance to metformin in breast cancer cells : The interaction of growth pathways and estrogen receptor signaling. In: IUBMB Life. 2016 ; Vol. 68, No. 4. pp. 281-292.
@article{be6f75ea74834a36b61fba963c8c7033,
title = "The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling",
abstract = "Metformin, a biguanide antidiabetic drug, is used to decrease hyperglycemia in patients with type 2 diabetes. Recently, the epidemiological studies revealed the potential of metformin as an anti-tumor drug for several types of cancer, including breast cancer. Anti-tumor metformin action was found to be mediated, at least in part, via activation of adenosine monophosphate-activated protein kinase (AMPK) - intracellular energy sensor, which inhibits the mammalian target of rapamycin (mTOR) and some other signaling pathways. Nevertheless, some patients can be non-sensitive or resistant to metformin action. Here we analyzed the mechanism of the formation of metformin-resistant phenotype in breast cancer cells and its role in estrogen receptor (ER) regulation. The experiments were performed on the ER-positive MCF-7 breast cancer cells and metformin-resistant MCF-7 subline (MCF-7/M) developed due to long-term metformin treatment. The transcriptional activity of NF-κB and ER was measured by the luciferase reporter gene analysis. The protein expression was determined by immunoblotting (Snail1, (phospho)AMPK, (phospho)IκBα, (phospho)mTOR, cyclin D1, (phospho)Akt and ERα) and immunohistochemical analysis (E-cadherin). We have found that: 1) metformin treatment of MCF-7 cells is accompanied with the stimulation of AMPK and inhibition of growth-related proteins including IκBα, NF-κB, cyclin D1 and ERα; 2) long-term metformin treatment lead to the appearance and progression of cross-resistance to metformin and tamoxifen; the resistant cells are characterized with the unaffected AMPK activity, but the irreversible ER suppression and constitutive activation of Akt/Snail1 signaling; 3) Akt/Snail1 signaling is involved into progression of metformin resistance. The results presented may be considered as the first evidence of the progression of cross-resistance to metformin and tamoxifen in breast cancer cells. Importantly, the acquired resistance to both drugs is based on the constitutive activation of Akt/Snail1/E-cadherin signaling that opens new perspectives to overcome the metformin/tamoxifen resistance of breast cancer.",
keywords = "breast cancer, cell signaling, epithelial-mesenchymal transition, metformin, signal transduction, signal transduction pathways",
author = "Scherbakov, {Alexander M.} and Sorokin, {Danila V.} and Tatarskiy, {Victor V.} and Nikolai Prokhorov and Semina, {Svetlana E.} and Berstein, {Lev M.} and Krasil'Nikov, {Mikhail A.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/iub.1481",
language = "English (US)",
volume = "68",
pages = "281--292",
journal = "IUBMB Life",
issn = "1521-6543",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The phenomenon of acquired resistance to metformin in breast cancer cells

T2 - The interaction of growth pathways and estrogen receptor signaling

AU - Scherbakov, Alexander M.

AU - Sorokin, Danila V.

AU - Tatarskiy, Victor V.

AU - Prokhorov, Nikolai

AU - Semina, Svetlana E.

AU - Berstein, Lev M.

AU - Krasil'Nikov, Mikhail A.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Metformin, a biguanide antidiabetic drug, is used to decrease hyperglycemia in patients with type 2 diabetes. Recently, the epidemiological studies revealed the potential of metformin as an anti-tumor drug for several types of cancer, including breast cancer. Anti-tumor metformin action was found to be mediated, at least in part, via activation of adenosine monophosphate-activated protein kinase (AMPK) - intracellular energy sensor, which inhibits the mammalian target of rapamycin (mTOR) and some other signaling pathways. Nevertheless, some patients can be non-sensitive or resistant to metformin action. Here we analyzed the mechanism of the formation of metformin-resistant phenotype in breast cancer cells and its role in estrogen receptor (ER) regulation. The experiments were performed on the ER-positive MCF-7 breast cancer cells and metformin-resistant MCF-7 subline (MCF-7/M) developed due to long-term metformin treatment. The transcriptional activity of NF-κB and ER was measured by the luciferase reporter gene analysis. The protein expression was determined by immunoblotting (Snail1, (phospho)AMPK, (phospho)IκBα, (phospho)mTOR, cyclin D1, (phospho)Akt and ERα) and immunohistochemical analysis (E-cadherin). We have found that: 1) metformin treatment of MCF-7 cells is accompanied with the stimulation of AMPK and inhibition of growth-related proteins including IκBα, NF-κB, cyclin D1 and ERα; 2) long-term metformin treatment lead to the appearance and progression of cross-resistance to metformin and tamoxifen; the resistant cells are characterized with the unaffected AMPK activity, but the irreversible ER suppression and constitutive activation of Akt/Snail1 signaling; 3) Akt/Snail1 signaling is involved into progression of metformin resistance. The results presented may be considered as the first evidence of the progression of cross-resistance to metformin and tamoxifen in breast cancer cells. Importantly, the acquired resistance to both drugs is based on the constitutive activation of Akt/Snail1/E-cadherin signaling that opens new perspectives to overcome the metformin/tamoxifen resistance of breast cancer.

AB - Metformin, a biguanide antidiabetic drug, is used to decrease hyperglycemia in patients with type 2 diabetes. Recently, the epidemiological studies revealed the potential of metformin as an anti-tumor drug for several types of cancer, including breast cancer. Anti-tumor metformin action was found to be mediated, at least in part, via activation of adenosine monophosphate-activated protein kinase (AMPK) - intracellular energy sensor, which inhibits the mammalian target of rapamycin (mTOR) and some other signaling pathways. Nevertheless, some patients can be non-sensitive or resistant to metformin action. Here we analyzed the mechanism of the formation of metformin-resistant phenotype in breast cancer cells and its role in estrogen receptor (ER) regulation. The experiments were performed on the ER-positive MCF-7 breast cancer cells and metformin-resistant MCF-7 subline (MCF-7/M) developed due to long-term metformin treatment. The transcriptional activity of NF-κB and ER was measured by the luciferase reporter gene analysis. The protein expression was determined by immunoblotting (Snail1, (phospho)AMPK, (phospho)IκBα, (phospho)mTOR, cyclin D1, (phospho)Akt and ERα) and immunohistochemical analysis (E-cadherin). We have found that: 1) metformin treatment of MCF-7 cells is accompanied with the stimulation of AMPK and inhibition of growth-related proteins including IκBα, NF-κB, cyclin D1 and ERα; 2) long-term metformin treatment lead to the appearance and progression of cross-resistance to metformin and tamoxifen; the resistant cells are characterized with the unaffected AMPK activity, but the irreversible ER suppression and constitutive activation of Akt/Snail1 signaling; 3) Akt/Snail1 signaling is involved into progression of metformin resistance. The results presented may be considered as the first evidence of the progression of cross-resistance to metformin and tamoxifen in breast cancer cells. Importantly, the acquired resistance to both drugs is based on the constitutive activation of Akt/Snail1/E-cadherin signaling that opens new perspectives to overcome the metformin/tamoxifen resistance of breast cancer.

KW - breast cancer

KW - cell signaling

KW - epithelial-mesenchymal transition

KW - metformin

KW - signal transduction

KW - signal transduction pathways

UR - http://www.scopus.com/inward/record.url?scp=84975764321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975764321&partnerID=8YFLogxK

U2 - 10.1002/iub.1481

DO - 10.1002/iub.1481

M3 - Article

C2 - 26892736

AN - SCOPUS:84975764321

VL - 68

SP - 281

EP - 292

JO - IUBMB Life

JF - IUBMB Life

SN - 1521-6543

IS - 4

ER -